|
| Press Releases |
|
 |
|
| Thursday, July 11, 2019 |
|
|
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019 |
| Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including the latest data of the anti-amyloid beta (A beta) protofibril antibody BAN2401 and the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat, will be given at the Alzheimer's Association International Conference (AAIC) 2019.. more info >> |
|
| Wednesday, July 10, 2019 |
|
|
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts |
| Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities. more info >> |
|
| Monday, July 8, 2019 |
|
|
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery |
| Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area. more info >> |
|
| Tuesday, June 18, 2019 |
|
|
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130 |
| Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin. more info >> |
|
|
Eisai to Present Latest Data on Perampanel at 33rd International Epilepsy Congress |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 33rd International Epilepsy Congress (IEC) to be held from June 22 to 26, 2019 in Bangkok, Thailand. more info >> |
|
| Wednesday, May 29, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting |
| Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States. more info >> |
|
| Friday, May 17, 2019 |
|
|
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets |
| Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative" for Eisai's mid and long-term targets for greenhouse gas (GHG) reduction. more info >> |
|
| Thursday, May 16, 2019 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting |
| Major poster presentations at this year's meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai's first ADC MORAb-202 in patients with solid tumors in Japan. more info >> |
|
| Friday, May 10, 2019 |
|
|
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan |
| Under the agreement, Eisai will obtain exclusive rights to market MTX subcutaneous injection in Japan. Medac will submit a manufacturing and marketing authorization application for the product after conducting a clinical study in Japan. more info >> |
|
|
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 |
| These studies will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health, and Eisai. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hola Prime and Pro Basketball Player Karl-Anthony Towns Team up for 'Speed is Success' Campaign, Redefining Prop Trading 
May 14, 2025 22:20 HKT/SGT
|
|
|
Business delegation concludes Middle East mission in Kuwait
May 14, 2025 21:37 HKT/SGT
|
|
|
Quotient Capital's Strategic Outlook for 2025
May 14, 2025 19:45 HKT/SGT
|
|
|
Staying Ahead in the Digital Era as AI Takes Full Center Stage at InfoComm Asia 2025 -- Visitor Registration Opens
May 14, 2025 18:29 HKT/SGT
|
|
|
MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station
May 14, 2025 16:50 JST
|
|
|
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT/SGT
|
|
|
Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects
May 14, 2025 11:00 JST
|
|
|
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud
May 13, 2025 19:00 HKT/SGT
|
|
|
Widespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research Finds
May 13, 2025 17:05 HKT/SGT
|
|
|
EdgePoint completes 12 projects under its Connectivity for Communities Program, impacting more than 6,500 students across Malaysia, Indonesia and the Philippines
May 13, 2025 15:00 HKT/SGT
|
|
|
Nissin Foods Announces 2025 Q1 Financial Results
May 13, 2025 12:47 HKT/SGT
|
|
|
Adyen and JCB launch Card-on-File Tokenization to Enhance Payment Security
May 13, 2025 11:00 JST
|
|
|
Business Delegation Forges New Collaborations in Qatar
May 12, 2025 22:02 HKT/SGT
|
|
|
Euro Manganese Announces Appointment of Ms. Martina Blahova as Permanent President & Chief Executive Officer
May 12, 2025 20:09 HKT/SGT
|
|
|
TOYOTA GAZOO Racing fights back for double points finish
May 12, 2025 15:45 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
